DAFTAR PUSTAKA 1. Magrath, Ian. Malignant non-hodgkins lymphomas in children. Dalam: Pizzo PA, Poplack DG, penyunting.

Principles and Practice of Pediatric Oncology. Philadelphia: JB Lippincott; 4nd ed., 2002. pp 681- 705. 2. Cavdar AO, Gozdasoglu S, Yavuz G. Burkitts lymphoma between african and american types in turkish children: clinical, viral (EBV), and molecular studies. Med Pediatric Oncol 1993;21:36-42. 3. Nafanti S, Windaastuti E, Gatot Djajadiman. Gambaran limfoma burkitt di departemen ilmu kesehatan anak rsupn cipto mangunkusumo jakarta. Sari pediatri 2008;10(2): 47-52 4. Orem J, Mbidde EK, Lambert B, Sanjose S, and Weiderpass E. Burkitts lymphoma in Africa; a review of the epidemiology and etiology. African Health Sciences 2007;7:166175. 5. God J M, Haque A. Burkitt lymphoma: pathogenesis and immune evasion. Journal of Oncology 2010;2010:1-14. 6. Molyneux EM, Rochford R, Griffin B, Newton R, Jackson R, Menon G, et al. Burkitts lymphoma. Lancet 2012; 379: 123444. 7. Bornkamm, GW. Epstein-Barr virus and the pathogenesis of burkitts lymphoma: more questions than answers. International Journal Cancer 2009; 124:174555. 8. Weinstein H J, Hudson M M, Link M P. Pediatric Lymphoma. Heidelberg: Springer; 2007. p. 151-162. 9. KrudyAG, Dunnick NR, Magrath IT, Shawker TH, Doppman JL, Spiegel R. CT of american burkitt lymphoma. American Journal Radiology 1981;136:747-754 10. Mosse C, Weck K. The molecular pathology of burkitt lymphoma dalam Molecular Pathology of Hematolymphoid Diseases, New York: Springer; 2010. p. 277-285 11. Troxell, Megan L, Bangs, Charles D, Cherry, Athena M, et al.Cytologic diagnosis of burkitt lymphoma. Cancer (Cancer Cytopathology) 2005; 105(5):310-317 12. Indrawati. Peranan pemeriksaan imunohistokimia pada limfoma non hodgkin sel B. Berkala Kesehatan Klinik 2008; 14: 114-19 13. Ferry, Judith A. Burkitts lymphoma: clinicopathologic features and differential diagnosis. The Oncologist 2006; 11:375-83 vi

14. Magrath, Ian. Towards curative therapy in burkitt lymphoma: the role of early african studies in demonstrating the value of combination therapy and cns prophylaxis. Advances in Hematology 2012; 130680: 1-7 15. Bleyer W A, Barr R D. Pediatric Oncology: Cancer In Adolescent And Young Adults. New York: Springer; 2007. p. 134-135 16. Traore F, Coze C, Atteby J J, Andre N, Moreira C, Doumbe P, et al. Cyclophosphamide monotherapy in children with burkitt lymphoma: a study from the FrenchAfrican pediatric oncology group (gfaop). Pediatric Blood Cancer 2011;56:7006 17. IARC Working Groups. Cyclophosphamide. IARC MONOGRAPHS; 100A : 63 -90 18. Priestman, Terry. Cancer Therapy in Clinical Practice. London: Springer; 2008. p. 17-23 19. Haubitz, M. Acute and long-term toxicity of cyclophosphamide. Transplantationsmedizin Medical School Hannover 2007;19: 26 20. Chan, Edwin S L, Cronstein, Bruce N. Molecular action of methotrexate in inflammatory diseases. Arthritis Research 2001: 4 ; 4 21. Tian H, Cronstein, B. Understanding the mechanisms of action of methotrexate. Bulletin of the NYU Hospital for Joint Diseases: 2007;65(3):168-73 22. Avinoam S, Stark B, Kornreich L, Cohen I, Avrahami G, Yaniv I. Methotrexate related neurotoxicity in the treatment of childhood acute lympoblastic leukemia. IMAJ 2002: 4; 1050-53 23. Yin B, Morgan K, Hasz D E, Mao Z, dan Largaespada D A. Nf1 gene inactivation in acute myeloid leukemia cells confer cytarabine resistance through MAPK and mTOR pathways. Leukemia, 20: 151-154 24. Lymphoma Forum Of Ireland. Guidelines Of Diagnosis And Treatment Of Malignant Lymphoma. Irlandia: Roche; 2010. p. 40 25. Gaurav D, Dhingra A, Kaushal D. Vincristine Induced Cranial Neuropathy. JAPI 2012: 60: 56-58. 26. Upmanyu R, Dvivedi J, Saxena Y. Hepatotoxic effects of vincristine : an experimental study on albino rats. Indian J Physiol Pharmacol 2009; 53(3): 265270.

vi